Changes in 18F-FDG-PET/CT tumor metabolism and prediction of pathologic complete response rates after neoadjuvant chemotherapy in hormone-positive breast cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e12088-e12088
Author(s):  
Serap Kaya ◽  
Bilge Aktas ◽  
Eda Tanrikulu Simsek ◽  
Mehmet Akif Ozturk ◽  
Fuat Dede ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Tumor Metabolism ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Positive Breast Cancer

scholarly journals Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
In Hee Lee ◽  
Soo Jung Lee ◽  
Jeeyeon Lee ◽  
Jin Hyang Jung ◽  
Ho Yong Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Predictive Factor ◽  
Fdg Pet ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Background Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative breast cancer, the response to NAC is variable and mostly limited. This study was an investigation of the predictive relevance of parameters of 18F-FDG PET/CT for the pCR to NAC in patients with HR-positive, HER2–negative breast cancer. Methods: AH total of 109 consecutive HR-positive and HER2-negative breast cancer patients who were treated with NAC were enrolled in this prospective cohort study. The relationships between pretreatment 18F-FDG PET/CT and clinical outcomes including pathologic response to NAC were evaluated. Results: All patients finished their planned NAC cycles and eight patients (7.3%) achieved pCR. In the receiver operating characteristic (ROC) curve analysis, pSUVmax exhibited high sensitivity and specificity for predicting pCR. Furthermore, multivariate logistic regression analysis revealed pSUVmax as a predictive factor for pCR (hazard ratio = 17.452; 95% CI = 1.847–164.892; p = 0.013). Conclusion The results of this study suggest that 18F-FDG PET/CT pSUVmax is a predictive factor for pCR of HR-positive, HER2-negative breast cancer to NAC.

18F-FDG-PET/CT in predicting pathologic complete response after neoadjuvant chemotherapy: The early metabolic response is the answer

2013 ◽  
Vol 49 (16) ◽  
pp. 3573-3574
Author(s):  
Salome Sanz-Viedma ◽  
Alfonso Sanchez-Muñoz ◽  
Victoria Scholz-Gutierrez ◽  
Jose Manuel Jimenez-Hoyuela ◽  
Abass Alavi ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Early Metabolic Response

HER2-positive breast cancer: Combined 18F-FDG PET and CGFL/Curie nomogram to predict pathologic complete response after preoperative chemotherapy with trastuzumab.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12095-e12095
Author(s):  
Laura Vincent ◽  
Clémentine Jankowski ◽  
Marion Cortet ◽  
Laurent Arnould ◽  
Sylvain Ladoire ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Pet Ct ◽  
Spearman Coefficient ◽  
Fdg Pet Ct ◽  
Positive Breast Cancer

e12095 Background: The aim of this study was to compare the value of 18F-fluorodesoxyglucose positron emission tomography (18F-FDG PET/CT) with CGFL/Curie nomogram to predict a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in women with human epidermal growth factor 2 (HER2)-positive breast cancer treated by trastuzumab. Methods: Fifty-one women with HER2-positive breast cancer treated with trastuzumab plus taxane-based NAC, were retrospectively included from January 2005 to December 2015. For 18F-FDG PET/CT, the analyzed predictor was the maximum standardized uptake value of the primary tumor and axillary nodes after the first course of NAC (PET2.SUVmax). pCR was defined by no residual infiltrative tumor but in situ tumor was accepted. Accuracy of CGFL/Curie nomogram and PET2.SUVmax was evaluated measuring sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV). For each predictor, receiver operating characteristic (ROC) curve was created. To evaluate the correlation between predictors, the Spearman coefficient was calculated. Combined prediction was evaluated testing predictor’s associations. Results: For CGFL/Curie nomogram’s performances, Se, Sp, PPV and NPV were respectively: 76% (CI95%: 58-90%), 57% (CI95%: 43-66%), 55% (CI95%: 42-65), 77% (CI95%: 59-90%). For PET2.SUVmax’s performances, Se, Sp, PPV and NPV were respectively: 67% (CI95%: 48-81%), 77% (CI95%: 64-97%), 67% (CI95%: 48-82%), 77% (CI95%: 64-87%). ROC curves for these predictors were similar; the areas under the curve were 0.6 (CI95%: 0.56-0.64) for PET2.SUVmax and 0.55 (CI95%: 0.50-0.59) for CGFL/Curie nomogram. Spearman coefficient was 0.23. Combined prediction was more efficient with Se at 80%, VPN at 76%, Sp at 78% and VPP at 81 %. Conclusions: CGFL/Curie nomogram and PET2.SUVmax were two efficient predictors of pCR in patients with HER2-positive breast cancer. Combined prediction has an improved accuracy.

scholarly journals Utility of 18F-FDG PET/CT for Predicting Pathologic Complete Response in Luminal HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

2020 ◽  
Author(s):  
In Hee Lee ◽  
Soo Jung Lee ◽  
Jeeyeon Lee ◽  
Jinhyang Jung ◽  
Hoyong Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Predictive Factor ◽  
Fdg Pet ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Purpose: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with luminal-type breast cancer, the response to NAC is variable and mostly limited. This study was an investigation of the predictive relevance of parameters of 18 F-FDG PET/CT for the pCR to NAC in patients with luminal HER2–negative breast cancer. Methods: A total of 109 consecutive hormone receptor-positive and HER2-negative breast cancer patients who were treated with NAC were enrolled in this prospective cohort study. The relationships between pretreatment 18 F-FDG PET/CT and clinical outcomes including pathologic response to NAC were evaluated. Results: All patients finished their planned NAC cycles and eight patients (7.3%) achieved pCR. In the receiver operating characteristic (ROC) curve analysis, pSUVmax exhibited high sensitivity and specificity for predicting pCR. Furthermore, multivariate logistic regression analysis revealed pSUVmax as a predictive factor for pCR (hazard ratio = 17.452; 95% CI = 1.847 – 164.892; p = 0.013). Conclusion: The results of this study suggest that 18 F-FDG PET/CT pSUVmax is a predictive factor for pCR of luminal HER2-negative breast cancer to NAC.

scholarly journals Utility of 18F-FDG PET/CT for predicting pathologic complete response in Hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

2020 ◽  
Author(s):  
In Hee Lee ◽  
Soo Jung Lee ◽  
Jeeyeon Lee ◽  
Jinhyang Jung ◽  
Hoyong Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Predictive Factor ◽  
Fdg Pet ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Background: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative breast cancer, the response to NAC is variable and mostly limited. This study was an investigation of the predictive relevance of parameters of 18F-FDG PET/CT for the pCR to NAC in patients with HR-positive, HER2–negative breast cancer. Methods: AH total of 109 consecutive HR-positive and HER2-negative breast cancer patients who were treated with NAC were enrolled in this prospective cohort study. The relationships between pretreatment 18F-FDG PET/CT and clinical outcomes including pathologic response to NAC were evaluated. Results: All patients finished their planned NAC cycles and eight patients (7.3%) achieved pCR. In the receiver operating characteristic (ROC) curve analysis, pSUVmax exhibited high sensitivity and specificity for predicting pCR. Furthermore, multivariate logistic regression analysis revealed pSUVmax as a predictive factor for pCR (hazard ratio = 17.452; 95% CI = 1.847 – 164.892; p = 0.013). Conclusion: The results of this study suggest that 18F-FDG PET/CT pSUVmax is a predictive factor for pCR of HR-positive, HER2-negative breast cancer to NAC.

Sign in / Sign up

Export Citation Format

Share Document